ado-trastuzumab emtansine,tucatinib,trastuzumab deruxtecan,capecitabine,ruxolitinib
novartis,daiichi sankyo,astrazeneca,incyte,seagen,roche
['mbc', 'capecitabine', 'ado,trastuzumab,emtansine', 'fam-trastuzumab', 'rux,(-crux),(-trux)', 'trastuzumab deruxtecan', 'tucatinib']
to clarify the acronyms flying around wh/ i think were misquoted at least once, in her2+ mbc v4.2023 2 line
fam-trastuzumab deruxtecan-nkim (cat 1, preferred) 3 line
tucatinib + trastuzumab + capecitabine (cat 1, preferred)
ado-trastuzumab emtansine (t-dm1) #asco23
Director Breast Oncology, Lifespan Cancer Institute, Legorreta Cancer Center Brown Univ | Medical Advisor @drloveresearch | #bcsm #clinicaltrials | Views Mine